X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
VENUS REMEDIES Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Quarterly Results   (VSRM)

Here are the latest quarterly results of VENUS REMEDIES. For more details, see the VENUS REMEDIES financial fact sheet and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

VENUS REMEDIES Quarterly Results

No. of Mths
Qtr. Ending
3
Sep-16
3
Dec-16
3
Mar-17
3
Jun-17
3
Sep-17
3
Dec-17
3
Mar-18
3
Jun-18
8-Qtr Chart
Click to enlarge
Net Sales Rs m1,071854798782905931932655 
Other income Rs m22311132 
Turnover Rs m1,073856801784906933935657 
Expenses Rs m878659614593735754838554 
Gross profit Rs m19319518418917117794101 
Depreciation Rs m1001159910275896282 
Interest Rs m83103808187849877 
Profit before tax Rs m11-2188105-62-56 
Tax Rs m00-37000320 
Profit after tax Rs m11-21458105-94-56 
Gross profit margin %18.022.823.024.218.819.010.115.5 
Effective tax rate %0.00.0-451.20.00.00.0-50.90.0 
Net profit margin %1.1-2.55.71.11.10.6-10.1-8.5 
Diluted EPS Rs 1.0 -1.8 4.0 0.7 0.8 0.5 -8.2 -4.9  
Diluted EPS (TTM) Rs 1.5 -0.1 4.1 3.9 3.7 6.0 -6.1 -11.7  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: VENUS REMEDIES 1QFY19 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   PIRAMAL ENTERPRISES  NOVARTIS  FULFORD INDIA  STRIDES SHASUN LTD  MERCK LTD  

Compare VENUS REMEDIES With:   PIRAMAL ENTERPRISES  NOVARTIS  FULFORD INDIA  STRIDES SHASUN LTD  MERCK LTD  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Energy and Metal Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours of trade and ended the day at their fresh record high levels.

Views on news

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 20, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS